---
schema_version: "secwatch.filing_event.v1"
accession: "0001100682-24-000025"
form_type: "8-K"
ticker: "CRL"
cik: "0001100682"
company_name: "CHARLES RIVER LABORATORIES INTERNATIONAL, INC."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:35:52.034103+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Charles River Q2 revenue falls 3.2% to $1.03B; slashes FY24 guidance on weak demand

## Summary
- GAAP EPS $1.74 (-7.9% YoY); Non-GAAP EPS $2.80 (+4.1%), Non-GAAP net income $144.9M (+4.8%).
- DSA organic revenue -5.0%, RMS organic -3.9%; Manufacturing organic +3.7%.
- Board authorized new $1.0B share repurchase plan, replacing prior $1.3B authorization.
- FY24 guided GAAP EPS $5.65-$5.95 (prior $7.60-$8.10); Non-GAAP EPS $9.90-$10.20 (prior $10.90-$11.40).
- Restructuring expected to yield >$150M annual savings; ~$100M realized in 2024.

## SEC filing metadata
- accession: 0001100682-24-000025
- form_type: 8-K
- ticker: CRL
- cik: 0001100682
- company_name: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1100682/000110068224000025/0001100682-24-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1100682/000110068224000025/crl-20240807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001100682-24-000025
- JSON: https://secwatch.observer/filing/0001100682-24-000025.json
- Plain text: https://secwatch.observer/filing/0001100682-24-000025.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.